11 feb Faster and Better Targeted Antibiotic Care with Investment in ShanX Medtech
Amsterdam, 8 January 2026 – Borski Fund is proud to announce its investment in ShanX Medtech, an Eindhoven-based health-tech innovator developing a groundbreaking diagnostic platform to combat antimicrobial resistance (AMR), with an initial market focus on the women’s health UTI sector. The company’s ultra-rapid point-of-care solution enables clinicians to determine the most effective antibiotic treatment within hours rather than days, significantly improving patient outcomes and reducing unnecessary prescriptions.
The investment is part of an oversubscribed seed round, complemented by additional funding received from their EU procurement contract launched by DG Hera and HaDEA, bringing ShanX’s total financing to €24 million. The round was led by Borski Fund having built a strong consortium alongside Invest-NL, NextGen Ventures, Brabantse Ontwikkelings Maatschappij (BOM), CbusineZ, and strategic angel investors.
Why this matters:
With antimicrobial resistance (AMR) escalating into a critical global health challenge, the need for rapid, accurate point-of-care solutions has never been more urgent. These solutions are essential to ensure correct prescribing from day one, helping to potentially limit the spread of AMR, improve patient outcomes, and reduce healthcare costs.
Current diagnostic methods often take several days to identify the appropriate treatment, leaving patients vulnerable as their condition worsens. ShanX’s pioneering technology changes this paradigm by delivering accurate antibiotic identification within the hour —transforming patient care and setting a new standard in the fight against AMR.
Quote from Borski Fund:
“Following an extensive market analysis of innovations addressing antimicrobial resistance, ShanX’s technology clearly emerged as best-in-class. While the initial focus is on women’s health and urinary tract infections, the platform offers substantial potential across a wide range of clinical indications. We are proud to support Sophia and her exceptional team in realising their ambitious vision,” said Simone Brummelhuis, Partner at Borski Fund.
Quote from ShanX:“We are excited to be working with the team at Borski, who led our recent €24M funding round. Throughout the process, the team demonstrated exceptional professionalism and fairness, and (most importantly) a truly founder-first mindset; which I’ve found rare.
Beyond the mechanics of the transaction, Borski consistently emphasized what truly matters: impact, diversity, and long-term value creation. They showed particular thoughtfulness around our initial clinical focus on urinary tract infections, a condition that disproportionately affects women, and understood both the medical urgency and societal relevance of this choice.
The Borski team not only recognizes problems of meaningful scale and opportunity, but also brings a holistic approach to supporting female-led entrepreneurship. Their conviction, insight, and values make them an outstanding partner in building companies that matter.” Sophia Shanko CEO and Founder
Next steps:
The funding will accelerate ShanX’s final development phase including clinical validation and regulatory approval, prior to market launch. With strong commercial traction and strategic partnerships already in place, ShanX is positioned to become a global leader in rapid diagnostics.
For more information, visit shanxmedtech.com.
